Results of a randomized, double-blind, placebo-controlled, phase 2 study, investigating the safety and efficacy of anti-factor XIIa monoclonal antibody garadacimab (CSL312) for prophylaxis of HAE Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Craig, T
  • Magerl, M
  • Levy, DS
  • Reshef, A
  • Lumry, WL
  • Martinez-Saguer, I
  • Jacobs, JS
  • Yang, WH
  • Ritchie, B
  • Aygoeren-Puersuen, E
  • Keith, Paul
  • Busse, P
  • Feuersenger, H
  • Jacobs, I
  • Pragst, I

publication date

  • August 1, 2020